Torreya

The Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) Hosted the 2023 Annual Conference

Retrieved on: 
Monday, April 3, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Volunteering, Yale University, Duke University, Associate Director of National Intelligence and Chief Information Officer, Clarivate, University, Speech, Protein, MBA, Multimedia, Penn, History of the University of Maryland, College Park, Lunch, Drug discovery, Coffee, Jazz Pharmaceuticals, Growth, Frontage, Amicus Therapeutics, Conference, Pharmaceutical industry, Management, Torreya, Delaware Valley

https://sapagp.org/ ) hosted its 21st Annual Conference at the Sheraton Valley Forge Hotel northwest of Philadelphia.

Key Points: 
  • https://sapagp.org/ ) hosted its 21st Annual Conference at the Sheraton Valley Forge Hotel northwest of Philadelphia.
  • The conference was a major event in the greater Philadelphia area, sponsored by twenty-six companies and attended by over five-hundred life scientists, pharmaceutical professionals, and business executives.
  • To capture the new reality of the biopharma industry, the 2023 annual conference featured a balanced programming on science, technology, business, and career development.
  • The 2023 SAPA-GP Annual Conference was an invigorating community gathering of life scientists, pharmaceutical professionals, and business executives representing all backgrounds, experiences, and achievements.

Stifel Closes Acquisition of Torreya Partners

Retrieved on: 
Wednesday, March 1, 2023
Biotechnology, Torreya, Publishing, NYSE, Acquisition, Research, Entrepreneurship, Conference, Miller Buckfire & Co., SF, Investment banking, Broker-dealer, Eaton Partners, Pharmaceutical industry, Security (finance), Incorporated, Stifel

ST. LOUIS, March 01, 2023 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the completion of its acquisition of Torreya Partners LLC (“Torreya”), further solidifying its position as a top global healthcare franchise.

Key Points: 
  • ST. LOUIS, March 01, 2023 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the completion of its acquisition of Torreya Partners LLC (“Torreya”), further solidifying its position as a top global healthcare franchise.
  • “Today marks another milestone for Stifel as we build on our leadership position across healthcare,” said Brad Raymond, Stifel Global Head of Investment Banking.
  • I am thrilled to welcome the Torreya team to Stifel.”
    Founded in 2007, Torreya brings to Stifel a deep specialization within life sciences, including biotechnology and pharmaceuticals.
  • “We are excited to join the Stifel platform,” added Tim Opler, Torreya Managing Director and Co-Founder.

Stifel to Acquire Torreya Partners

Retrieved on: 
Thursday, December 22, 2022
Investment banking, Partnership, Biotechnology, Research, Knowledge, Broker-dealer, Sale, NYSE, Eaton Partners, Torreya, Conference, SF, Publishing, Miller Buckfire & Co., Bank, Incorporated, Stifel

ST. LOUIS, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced it has signed a definitive agreement to acquire Torreya Partners LLC (“Torreya”), a leading independent M&A and private capital advisory firm serving the global life sciences industry.

Key Points: 
  • ST. LOUIS, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced it has signed a definitive agreement to acquire Torreya Partners LLC (“Torreya”), a leading independent M&A and private capital advisory firm serving the global life sciences industry.
  • “We view Stifel as the right partner to help us accelerate growth across industry, product, and geographic coverage,” noted Tim Opler, Torreya Managing Director and Co-Founder.
  • Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; and Stifel Independent Advisors, LLC.
  • Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions.

DGAP-News: Sixteenth Annual BIO-Europe Spring(R) Digital to bring together over 2,000 life science leaders

Retrieved on: 
Friday, March 11, 2022
MSD, Norwest Venture Partners, Insilico Medicine, Industry, Catalent, Evotec, Business, Eli Lilly and Company, VP, General manager, Therapy, EVP, Tosin Abasi, CBO, Ipsen, SVP, List of Medknow Publications academic journals, Disease, Program, Samsung, Informa, Corporation, Eli Lilly, AGC, Video game, Pharmaceutical industry, Fine chemical, Torreya

The 16th annual BIO-Europe Spring(R) global life sciences partnering event will be held March 28-31, 2022 in a fully digital format.

Key Points: 
  • The 16th annual BIO-Europe Spring(R) global life sciences partnering event will be held March 28-31, 2022 in a fully digital format.
  • The event is expected to bring together over 2,000 executives from 1,200 life sciences companies spanning an estimated 50+ countries to engage in one-to-one partnering.
  • Gain digital access to four global partnering events, including BIO-Europe Spring, when you register for our Global Partnering Virtual Passport .
  • EBD Group's overriding mission is to help collaborations get started across the life science value chain.

Iktos Announces Deployment of Their AI for Drug Design Software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Retrieved on: 
Wednesday, December 8, 2021
Technology, Research, Medical Devices, Clinical Trials, Software, Biotechnology, Health, Pharmaceutical, Science, Cloud, Tao, Torreya, Jiangsu Hengrui Medicine, Analysis, Korea Carbon Capture & Sequestration R&D Center, Project Jupyter, Research, VPC, Technology, Pharma, Disease, Drug discovery, Artificial intelligence, Efficiency, CEO, Software, Deep learning, Virtual private cloud, Drug design, Intelligence, MPO, Solution, AI, Software as a service, De novo, Pharmaceutical industry, Fine chemical, Iktos, Jiangsu Hengrui Pharmaceuticals Co., Ltd., IKTOS, JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Under the agreement, Iktos de novo generative design software Makya will be used by Hengrui scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Hengrui Pharmas drug discovery programmes.

Key Points: 
  • Under the agreement, Iktos de novo generative design software Makya will be used by Hengrui scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Hengrui Pharmas drug discovery programmes.
  • This tackles one of the key challenges in drug design: rapid identification of molecules which simultaneously satisfy multiple bioactivity and drug-like criteria for drug discovery and development.
  • Innovation is the core development strategy, said Dr. Weikang Tao, Vice President of Hengrui Pharma and CEO of R&D Centers.
  • We are excited about the opportunity to use Iktos proprietary AI platform to beef up our drug design and discovery capability to better address unmet clinical needs.

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

Retrieved on: 
Sunday, November 21, 2021
Patient, Senior, CEO, Safety, Greater, HKEX, Partnership, Cancer, Mab, Cytotoxic T cell, Microsatellite instability, Torreya, R, Research, Board, IO, CD152, Fine chemical, Pharmaceutical industry, Vaccine

Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.

Key Points: 
  • Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.
  • CStone will retain the rights to develop and commercialize of CS1002 outside of Greater China.
  • There is only one anti-CTLA-4 monoclonal antibody approved globally, and it is also approved in China.
  • Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan.

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

Retrieved on: 
Sunday, November 21, 2021
Patient, Senior, CEO, Safety, Greater, HKEX, Partnership, Cancer, Mab, Cytotoxic T cell, Microsatellite instability, Torreya, R, Research, Board, IO, CD152, Fine chemical, Pharmaceutical industry, Vaccine

Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.

Key Points: 
  • Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.
  • CStone will retain the rights to develop and commercialize of CS1002 outside of Greater China.
  • There is only one anti-CTLA-4 monoclonal antibody approved globally, and it is also approved in China.
  • Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan.

Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts

Retrieved on: 
Thursday, April 22, 2021
Health, Infectious diseases, Surgery, General Health, Pharmaceutical, Biotechnology, Drugs, Clinical medicine, Psychoactive drugs, Euphoriants, Ketones, Analgesics, General anesthetics, Enkephalin, Nasal administration, Ketamine, Chronic pain, Torreya, Virpax Pharmaceuticals, TORREYA, VIRPAX PHARMACEUTICALS

Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.

Key Points: 
  • Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.
  • We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, capital markets, licensing, and asset sale transactions.
  • Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence.
  • Envelta\xe2\x84\xa2 is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

Eastman and GP Cellulose provide critical support for longleaf pine restoration in Florida

Retrieved on: 
Friday, March 19, 2021
Florida, Plants, Longleaf pine, States of the United States, Torreya State Park, Torreya

BRISTOL, Fla., March 19, 2021 /PRNewswire/ -- In celebration of the International Day of Forests on March 21, Eastman , Eastman Foundation and GP Cellulose worked with The Longleaf Alliance (LLA) to provide 60,000 longleaf pine seedlings to Torreya State Park in Northwest Florida.

Key Points: 
  • BRISTOL, Fla., March 19, 2021 /PRNewswire/ -- In celebration of the International Day of Forests on March 21, Eastman , Eastman Foundation and GP Cellulose worked with The Longleaf Alliance (LLA) to provide 60,000 longleaf pine seedlings to Torreya State Park in Northwest Florida.
  • Eastman Foundation and GP funded the conservation project due to their shared commitment to restoring and maintaining these fragile forest ecosystems.
  • "Guiding the restoration, stewardship, and conservation of longleaf pine ecosystems is core to the function of The Longleaf Alliance.
  • We are thrilled to be working with Eastman, GP Cellulose and Florida State Parks to restore longleaf habitat at Torreya State Park.